News
SDZXF
67.00
NaN%
--
Analysts Offer Insights on Healthcare Companies: Sandoz Group Ltd (OtherSDZXF) and Kuros Biosciences (OtherCSBTF)
TipRanks · 1d ago
Morgan Stanley Reaffirms Their Hold Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 1d ago
Sandoz Launches Denosumab Biosimilars in Europe to Expand Affordable Treatment Options
TipRanks · 3d ago
Sandoz Launches Denosumab Biosimilars in Europe
Reuters · 3d ago
Sandoz Expands European Market with Afqlir® Launch for Retinal Diseases
TipRanks · 11/24 06:33
Sandoz Wins European Commission Approval for Afqlir Biosimilar Aflibercept
Reuters · 11/24 06:21
PRESS DIGEST-Canada - Nov 21
Reuters · 11/21 13:49
Sandoz Group Ltd (SDZXF) Gets a Buy from Kepler Capital
TipRanks · 11/19 01:45
Mirum Pharmaceuticals Sues Sandoz Over Proposed Generic Livmarli
Reuters · 11/17 21:53
Sandoz price target raised to CHF 60 from CHF 55 at Deutsche Bank
TipRanks · 11/17 19:25
Sandoz Launches First FDA-Approved MS Biosimilar in US
TipRanks · 11/17 06:34
Sandoz Launches First FDA-Approved Multiple Sclerosis Biosimilar TYRUKO in US
Reuters · 11/17 06:02
Kepler Capital Keeps Their Buy Rating on Sandoz Group Ltd (SDZXF)
TipRanks · 11/14 01:46
Sandoz Group AG Laboratories Achieve My Green Lab Certification
Reuters · 11/13 09:25
UPDATE 1-Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2
Reuters · 11/12 15:09
SANDOZ GROUP CEO EXPECTS DEMAND FROM DIABETES PATIENTS TO "BE WAY IN EXCESS" OF SUPPLY FOR SEMAGLUTIDE BIOSIMILAR IN CANADA
Reuters · 11/12 14:52
SANDOZ GROUP CEO RICHARD SAYNOR EXPECTS SEMAGLUTIDE BIOSIMILARS TO LAUNCH IN Q1, Q2 NEXT YEAR IN CANADA - INTERVIEW
Reuters · 11/12 14:52
Sandoz Expands Oncology Portfolio with Global License for Pertuzumab Biosimilar
TipRanks · 11/12 08:07
Sandoz price target raised to CHF 60 from CHF 55 at JPMorgan
TipRanks · 11/10 19:25
Sandoz Report Warns of Growing Threat to European Antibiotics Supply
Reuters · 11/10 08:33
More
Webull provides a variety of real-time SDZXF stock news. You can receive the latest news about Sandoz Group AG through multiple platforms. This information may help you make smarter investment decisions.
About SDZXF
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.